Corvus Pharmaceuticals, Inc.

Informe acción NasdaqGM:CRVS

Capitalización de mercado: US$591.1m

Corvus Pharmaceuticals Resultados de beneficios anteriores

Pasado controles de criterios 0/6

Corvus Pharmaceuticals ha aumentado sus beneficios a una tasa media anual de 6.6%, mientras que la industria Biotechs ha visto sus beneficios crecer en un 19.3% anualmente.

Información clave

6.6%

Tasa de crecimiento de los beneficios

21.6%

Tasa de crecimiento del BPA

Crecimiento de la industria Biotechs 17.0%
Tasa de crecimiento de los ingresosn/a
Rentabilidad financiera-44.1%
Margen neton/a
Próxima actualización de resultados12 Nov 2024

Actualizaciones de resultados anteriores recientes

Recent updates

Corvus Pharmaceuticals: Soquelitinib's High Stakes In PTCL Therapy

Sep 02

Will Corvus Pharmaceuticals (NASDAQ:CRVS) Spend Its Cash Wisely?

Mar 06
Will Corvus Pharmaceuticals (NASDAQ:CRVS) Spend Its Cash Wisely?

Here's Why We're Watching Corvus Pharmaceuticals' (NASDAQ:CRVS) Cash Burn Situation

Oct 23
Here's Why We're Watching Corvus Pharmaceuticals' (NASDAQ:CRVS) Cash Burn Situation

Is Corvus Pharmaceuticals (NASDAQ:CRVS) In A Good Position To Invest In Growth?

May 16
Is Corvus Pharmaceuticals (NASDAQ:CRVS) In A Good Position To Invest In Growth?

Here's Why We're Watching Corvus Pharmaceuticals' (NASDAQ:CRVS) Cash Burn Situation

Dec 05
Here's Why We're Watching Corvus Pharmaceuticals' (NASDAQ:CRVS) Cash Burn Situation

Corvus' partner Angel Pharma gets nod to start phase 1/1b trial of cancer therapy in China

Sep 26

We're Keeping An Eye On Corvus Pharmaceuticals' (NASDAQ:CRVS) Cash Burn Rate

Aug 14
We're Keeping An Eye On Corvus Pharmaceuticals' (NASDAQ:CRVS) Cash Burn Rate

Companies Like Corvus Pharmaceuticals (NASDAQ:CRVS) Are In A Position To Invest In Growth

Apr 05
Companies Like Corvus Pharmaceuticals (NASDAQ:CRVS) Are In A Position To Invest In Growth

We're Hopeful That Corvus Pharmaceuticals (NASDAQ:CRVS) Will Use Its Cash Wisely

Dec 15
We're Hopeful That Corvus Pharmaceuticals (NASDAQ:CRVS) Will Use Its Cash Wisely

Checking In On Corvus Pharmaceuticals

Dec 10

Corvus: Surging On AstraZeneca CD73 Success With Key Data Readout Looming

Sep 22

We Think Corvus Pharmaceuticals (NASDAQ:CRVS) Can Afford To Drive Business Growth

Aug 26
We Think Corvus Pharmaceuticals (NASDAQ:CRVS) Can Afford To Drive Business Growth

Corvus Pharmaceuticals initiated buy at Cantor with a Street-high target

May 27

Is Corvus Pharmaceuticals (NASDAQ:CRVS) In A Good Position To Deliver On Growth Plans?

May 08
Is Corvus Pharmaceuticals (NASDAQ:CRVS) In A Good Position To Deliver On Growth Plans?

The Co-Founder of Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS), Richard Miller, Just Bought 8.5% More Shares

Feb 19
The Co-Founder of Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS), Richard Miller, Just Bought 8.5% More Shares

Here's Why We're Watching Corvus Pharmaceuticals' (NASDAQ:CRVS) Cash Burn Situation

Feb 07
Here's Why We're Watching Corvus Pharmaceuticals' (NASDAQ:CRVS) Cash Burn Situation

Here's What Corvus Pharmaceuticals, Inc.'s (NASDAQ:CRVS) Shareholder Ownership Structure Looks Like

Dec 16
Here's What Corvus Pharmaceuticals, Inc.'s (NASDAQ:CRVS) Shareholder Ownership Structure Looks Like

Corvus Pharmaceuticals EPS misses by $0.06

Oct 29

Desglose de ingresos y gastos

Cómo gana y gasta dinero Corvus Pharmaceuticals. Basado en los últimos beneficios reportados, en base a los últimos doce meses (LTM).


Historial de beneficios e ingresos

NasdaqGM:CRVS Ingresos, gastos y beneficios (USD Millions)
FechaIngresosBeneficiosGastos G+AGastos de I+D
30 Jun 240-23716
31 Mar 240-25716
31 Dec 230-27717
30 Sep 230-30717
30 Jun 230-39723
31 Mar 230-41724
31 Dec 220-41824
30 Sep 220-41825
30 Jun 220-37822
31 Mar 220-40826
31 Dec 210-43929
30 Sep 210-71032
30 Jun 210-61131
31 Mar 210-51230
31 Dec 200-61232
30 Sep 200-441234
30 Jun 200-461136
31 Mar 200-481139
31 Dec 190-471138
30 Sep 190-461137
30 Jun 190-461137
31 Mar 190-441136
31 Dec 180-471139
30 Sep 180-481040
30 Jun 180-511042
31 Mar 180-541045
31 Dec 170-561046
30 Sep 170-551046
30 Jun 170-521043
31 Mar 170-46937
31 Dec 160-36829
30 Sep 160-31724
30 Jun 160-24519
31 Mar 160-36414
31 Dec 150-31211
30 Sep 150-2516

Ingresos de calidad: CRVS actualmente no es rentable.

Margen de beneficios creciente: CRVS actualmente no es rentable.


Análisis del flujo de caja libre vs. Beneficios


Análisis del crecimiento de los beneficios en el pasado

Tendencia de beneficios: CRVS no es rentable, pero ha reducido pérdidas en los últimos 5 años a un ritmo de 6.6% por año.

Acelerando crecimiento: No se puede comparar el crecimiento de los beneficios de CRVS en el último año con su promedio de 5 años, ya que actualmente no es rentable.

Beneficios vs. Industria: CRVS no es rentable, por lo que resulta difícil comparar el crecimiento de sus beneficios en el último año con el de la industria Biotechs (16.6%).


Rentabilidad financiera

Alta ROE: CRVS tiene una rentabilidad financiera negativa (-44.15%), ya que actualmente no es rentable.


Rentabilidad económica


Rendimiento del capital invertido


Descubre empresas con buenos resultados en el pasado